Search research articles
Contact Us
Filters
Showing results (21-30 of 32) with videos related to
Page
of 4
Sort By:
Pharmaceutics
|
April 25, 2019
Biodistribution and Physiologically-Based Pharmacokinetic Modeling of Gold Nanoparticles in Mice with Interspecies Extrapolation
Mohamed Aborig, Paul R V Malik, Shruti Nambiar, et al.
British Journal of Clinical Pharmacology
|
June 7, 2024
Infliximab in paediatric inflammatory bowel disease: External evaluation of population pharmacokinetic models
Omnia Salah Heikal, Patrick F van Rheenen, Daan J Touw, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
March 20, 2021
Limited sampling strategies for accurate determination of extended half-life factor VIII pharmacokinetics in severe haemophilia A patients
Alanna McEneny-King, Pierre Chelle, Margaret H Goggans, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
April 14, 2022
Revised terminal half-life of nonacog alfa as derived from extended sampling data: A real-world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis
Brigitte Tardy, Thierry Lambert, Pierre Chamouni, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
February 21, 2024
Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada
Davide Matino, Federico Germini, Anthony K C Chan, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
May 23, 2019
Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients
Pierre Chelle, Cindy H T Yeung, Santiago Bonanad, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
July 15, 2019
Correction to: Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients
Pierre Chelle, Cindy H T Yeung, Santiago Bonanad, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
February 29, 2020
Multicentre pharmacokinetic evaluation of rFVIII-Fc (efmoroctocog alfa) in a real life and comparison with non-extended half-life FVIII concentrates
Claire Pouplard, Laurent Sattler, Anne Ryman, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
September 24, 2025
An Open-Source Framework for Virtual Bioequivalence Modeling and Clinical Trial Design
Abdullah Hamadeh, Moriah Pellowe, Pierre Chelle, et al.
Journal of Thrombosis and Haemostasis : JTH
|
May 1, 2019
Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
Manuel D Carcao, Pierre Chelle, Emily Clarke, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 32) with videos related to
Sort By:
Page
of 4
Pharmaceutics
|
April 25, 2019
Biodistribution and Physiologically-Based Pharmacokinetic Modeling of Gold Nanoparticles in Mice with Interspecies Extrapolation
Mohamed Aborig, Paul R V Malik, Shruti Nambiar, et al.
British Journal of Clinical Pharmacology
|
June 7, 2024
Infliximab in paediatric inflammatory bowel disease: External evaluation of population pharmacokinetic models
Omnia Salah Heikal, Patrick F van Rheenen, Daan J Touw, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
March 20, 2021
Limited sampling strategies for accurate determination of extended half-life factor VIII pharmacokinetics in severe haemophilia A patients
Alanna McEneny-King, Pierre Chelle, Margaret H Goggans, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
April 14, 2022
Revised terminal half-life of nonacog alfa as derived from extended sampling data: A real-world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis
Brigitte Tardy, Thierry Lambert, Pierre Chamouni, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
February 21, 2024
Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada
Davide Matino, Federico Germini, Anthony K C Chan, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
May 23, 2019
Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients
Pierre Chelle, Cindy H T Yeung, Santiago Bonanad, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
July 15, 2019
Correction to: Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients
Pierre Chelle, Cindy H T Yeung, Santiago Bonanad, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
February 29, 2020
Multicentre pharmacokinetic evaluation of rFVIII-Fc (efmoroctocog alfa) in a real life and comparison with non-extended half-life FVIII concentrates
Claire Pouplard, Laurent Sattler, Anne Ryman, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
September 24, 2025
An Open-Source Framework for Virtual Bioequivalence Modeling and Clinical Trial Design
Abdullah Hamadeh, Moriah Pellowe, Pierre Chelle, et al.
Journal of Thrombosis and Haemostasis : JTH
|
May 1, 2019
Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
Manuel D Carcao, Pierre Chelle, Emily Clarke, et al.
Page
of 4